Johnson & Johnson
NYSE:JNJ

Watchlist Manager
Johnson & Johnson Logo
Johnson & Johnson
NYSE:JNJ
Watchlist
Price: 151.73 USD 2.04% Market Closed
Market Cap: 365.6B USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one JNJ stock under the Base Case scenario is 175.37 USD. Compared to the current market price of 151.73 USD, Johnson & Johnson is Undervalued by 13%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

JNJ Relative Value
Base Case
175.37 USD
Undervaluation 13%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

4.1
P/S
P/S
Price to Sales
4.1
vs History
90
vs Industry
28
Median 3Y
4.6
Median 5Y
4.5
Industry
2.3
Forward
4
More Details
26
P/E
P/E
Price to Earnings
26
vs History
25
vs Industry
16
Median 3Y
22.1
Median 5Y
22.1
Industry
19.8
Forward
14.2
More Details
15.1
P/OCF
P/OCF
Price to OCF
15.1
vs History
85
vs Industry
27
Median 3Y
17
Median 5Y
16.3
Industry
14.8
More Details
13.2
P/FCFE
P/FCFE
Price to FCFE
13.2
vs History
87
vs Industry
26
Median 3Y
16.9
Median 5Y
16.6
Industry
22.2
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
85
vs Industry
13
Median 3Y
5.3
Median 5Y
5.5
Industry
1.9
More Details
4.2
EV/S
EV/S
Enterprise Value to Sales
4.2
vs History
88
vs Industry
26
Median 3Y
4.7
Median 5Y
4.6
Industry
2.4
Forward
4.1
More Details
6.1
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.1
vs History
92
vs Industry
32
Median 3Y
6.8
Median 5Y
6.7
Industry
4.7
More Details
12.2
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
12.2
vs History
77
vs Industry
28
Median 3Y
13
Median 5Y
13.2
Industry
12
Forward
11.5
More Details
16
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
16
vs History
79
vs Industry
25
Median 3Y
16.9
Median 5Y
17.4
Industry
14.9
Forward
12.6
More Details
15.5
EV/OCF
EV/OCF
Enterprise Value to OCF
15.5
vs History
82
vs Industry
26
Median 3Y
17.2
Median 5Y
16.6
Industry
13.3
More Details
18.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
18.9
vs History
79
vs Industry
22
Median 3Y
21.2
Median 5Y
19.7
Industry
17.2
More Details
2.6
EV/IC
EV/IC
Enterprise Value to IC
2.6
vs History
88
vs Industry
27
Median 3Y
2.7
Median 5Y
2.7
Industry
1.7
More Details

Multiples Across Competitors

JNJ Competitors Multiples
Johnson & Johnson Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Johnson & Johnson
NYSE:JNJ
365.2B USD 4.1 26 12.2 16
US
Eli Lilly and Co
NYSE:LLY
694B USD 15.4 65.5 38.2 42.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
1.9T DKK 6.4 18.5 12.2 13.9
CH
Roche Holding AG
SIX:ROG
194.4B CHF 3.3 16.9 9.6 11.3
CH
Novartis AG
SIX:NOVN
174.3B CHF 4.1 17.9 10.9 13.9
UK
AstraZeneca PLC
LSE:AZN
155.2B GBP 3.8 28.9 125.6 191.8
US
Merck & Co Inc
NYSE:MRK
200.5B USD 3.1 11.7 8 9.4
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
FR
Sanofi SA
PAR:SAN
111.8B EUR 2.5 19.5 8.5 12.5
US
Pfizer Inc
NYSE:PFE
124.1B USD 2 15.5 7.7 11
P/E Multiple
Earnings Growth PEG
US
Johnson & Johnson
NYSE:JNJ
Average P/E: 24.5
26
26%
1
US
Eli Lilly and Co
NYSE:LLY
65.5
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
18.5
19%
1
CH
Roche Holding AG
SIX:ROG
16.9
16%
1.1
CH
Novartis AG
SIX:NOVN
17.9
16%
1.1
UK
AstraZeneca PLC
LSE:AZN
28.9
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.7
18%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
FR
Sanofi SA
PAR:SAN
19.5
28%
0.7
US
Pfizer Inc
NYSE:PFE
15.5
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBITDA: 394.4
12.2
8%
1.5
US
Eli Lilly and Co
NYSE:LLY
38.2
31%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
DK
Novo Nordisk A/S
CSE:NOVO B
12.2
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.6
7%
1.4
CH
Novartis AG
SIX:NOVN
10.9
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
125.6
9%
14
US
Merck & Co Inc
NYSE:MRK
8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
FR
Sanofi SA
PAR:SAN
8.5
6%
1.4
US
Pfizer Inc
NYSE:PFE
7.7
3%
2.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Johnson & Johnson
NYSE:JNJ
Average EV/EBIT: 1 697.7
16
12%
1.3
US
Eli Lilly and Co
NYSE:LLY
42.2
33%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
16%
0.9
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.9
8%
1.7
UK
AstraZeneca PLC
LSE:AZN
191.8
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.4
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
FR
Sanofi SA
PAR:SAN
12.5
14%
0.9
US
Pfizer Inc
NYSE:PFE
11
10%
1.1

See Also

Summary
JNJ intrinsic value, competitors valuation, and company profile.
DCF Valuation
JNJ stock valuation using Discount Cash Flow valuation method.
Relative Valuation
JNJ stock valuation using valuation multiples.
Wall Street Estimates
JNJ price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
JNJ stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 246,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.